161 related articles for article (PubMed ID: 31289348)
21. Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei.
Dutschmann M; Menuet C; Stettner GM; Gestreau C; Borghgraef P; Devijver H; Gielis L; Hilaire G; Van Leuven F
J Neurosci; 2010 Feb; 30(5):1810-21. PubMed ID: 20130190
[TBL] [Abstract][Full Text] [Related]
22. VPS35 haploinsufficiency increases Alzheimer's disease neuropathology.
Wen L; Tang FL; Hong Y; Luo SW; Wang CL; He W; Shen C; Jung JU; Xiong F; Lee DH; Zhang QG; Brann D; Kim TW; Yan R; Mei L; Xiong WC
J Cell Biol; 2011 Nov; 195(5):765-79. PubMed ID: 22105352
[TBL] [Abstract][Full Text] [Related]
23. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341
[TBL] [Abstract][Full Text] [Related]
24. Neurotrophin receptor p75 mediates amyloid β-induced tau pathology.
Shen LL; Li WW; Xu YL; Gao SH; Xu MY; Bu XL; Liu YH; Wang J; Zhu J; Zeng F; Yao XQ; Gao CY; Xu ZQ; Zhou XF; Wang YJ
Neurobiol Dis; 2019 Dec; 132():104567. PubMed ID: 31394202
[TBL] [Abstract][Full Text] [Related]
25. VPS35, the Retromer Complex and Parkinson's Disease.
Williams ET; Chen X; Moore DJ
J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
[TBL] [Abstract][Full Text] [Related]
26. Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice.
Giannopoulos PF; Chiu J; Praticò D
Aging Cell; 2018 Jun; 17(3):e12759. PubMed ID: 29607621
[TBL] [Abstract][Full Text] [Related]
27. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
[TBL] [Abstract][Full Text] [Related]
28. Learning Impairments, Memory Deficits, and Neuropathology in Aged Tau Transgenic Mice Are Dependent on Leukotrienes Biosynthesis: Role of the cdk5 Kinase Pathway.
Giannopoulos PF; Chiu J; Praticò D
Mol Neurobiol; 2019 Feb; 56(2):1211-1220. PubMed ID: 29881943
[TBL] [Abstract][Full Text] [Related]
29. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of 5-Lipoxygenase Worsens the Phenotype of a Mouse Model of Tauopathy.
Giannopoulos PF; Praticò D
Mol Neurobiol; 2018 Jul; 55(7):5926-5936. PubMed ID: 29128902
[TBL] [Abstract][Full Text] [Related]
31. Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain.
Narasimhan S; Guo JL; Changolkar L; Stieber A; McBride JD; Silva LV; He Z; Zhang B; Gathagan RJ; Trojanowski JQ; Lee VMY
J Neurosci; 2017 Nov; 37(47):11406-11423. PubMed ID: 29054878
[TBL] [Abstract][Full Text] [Related]
32. The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport.
Bhalla A; Vetanovetz CP; Morel E; Chamoun Z; Di Paolo G; Small SA
Neurobiol Dis; 2012 Jul; 47(1):126-34. PubMed ID: 22516235
[TBL] [Abstract][Full Text] [Related]
33. Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.
Arner A; Rockenstein E; Mante M; Florio J; Masliah D; Salehi B; Adame A; Overk C; Masliah E; Rissman RA
J Alzheimers Dis; 2018; 61(3):1201-1219. PubMed ID: 29332037
[TBL] [Abstract][Full Text] [Related]
34. Human tau expression reduces adult neurogenesis in a mouse model of tauopathy.
Komuro Y; Xu G; Bhaskar K; Lamb BT
Neurobiol Aging; 2015 Jun; 36(6):2034-42. PubMed ID: 25863528
[TBL] [Abstract][Full Text] [Related]
35. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.
Miura E; Hasegawa T; Konno M; Suzuki M; Sugeno N; Fujikake N; Geisler S; Tabuchi M; Oshima R; Kikuchi A; Baba T; Wada K; Nagai Y; Takeda A; Aoki M
Neurobiol Dis; 2014 Nov; 71():1-13. PubMed ID: 25107340
[TBL] [Abstract][Full Text] [Related]
36. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
[TBL] [Abstract][Full Text] [Related]
37. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
38. Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate.
Bondulich MK; Guo T; Meehan C; Manion J; Rodriguez Martin T; Mitchell JC; Hortobagyi T; Yankova N; Stygelbout V; Brion JP; Noble W; Hanger DP
Brain; 2016 Aug; 139(Pt 8):2290-306. PubMed ID: 27297240
[TBL] [Abstract][Full Text] [Related]
39. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
40. VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function.
Tang FL; Liu W; Hu JX; Erion JR; Ye J; Mei L; Xiong WC
Cell Rep; 2015 Sep; 12(10):1631-43. PubMed ID: 26321632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
